D. E. Shaw & Co., Inc. Xenon Pharmaceuticals Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 161,722 shares of XENE stock, worth $6.59 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

161,722

Previous 198,526 18.54%

Holding current value

$6.59 Million

Previous $8.55 Million 26.22%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $1.33 Million - $1.61 Million	-36,804 Reduced 18.54%	161,722 $6.31 Million
Q1 2024 May 15, 2024	BUY	$42.66 - $50.04 $4.88 Million - $5.72 Million	114,373 Added 135.91%	198,526 $8.55 Million
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $1.25 Million - $2.03 Million	43,606 Added 107.54%	84,153 $3.88 Million
Q3 2023 Nov 14, 2023	SELL	$34.16 - $39.73 $1.99 Million - $2.31 Million	-58,198 Reduced 58.94%	40,547 $1.39 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $3.76 Million - $4.7 Million	-107,927 Reduced 52.22%	98,745 $3.8 Million
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $5.14 Million - $6.2 Million	-153,749 Reduced 42.66%	206,672 $7.4 Million
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $1.62 Million - $1.94 Million	-49,142 Reduced 12.0%	360,421 $14.2 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $2.56 Million - $3.31 Million	83,021 Added 25.42%	409,563 $14.8 Million
Q2 2022 Aug 15, 2022	SELL	$25.44 - $35.16 $101,378 - $140,112	-3,985 Reduced 1.21%	326,542 $9.93 Million
Q1 2022 May 16, 2022	SELL	$25.09 - $33.13 $3.63 Million - $4.79 Million	-144,613 Reduced 30.44%	330,527 $10.1 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $5.09 Million - $11.5 Million	326,261 Added 219.15%	475,140 $14.8 Million
Q3 2021 Nov 15, 2021	SELL	$14.86 - $19.45 $225,753 - $295,484	-15,192 Reduced 9.26%	148,879 $2.28 Million
Q2 2021 Aug 16, 2021	SELL	$16.81 - $20.0 $183,632 - $218,480	-10,924 Reduced 6.24%	164,071 $3.06 Million
Q1 2021 May 17, 2021	SELL	$13.65 - $21.31 $119,369 - $186,355	-8,745 Reduced 4.76%	174,995 $3.13 Million
Q4 2020 Feb 16, 2021	SELL	$9.49 - $16.04 $81,357 - $137,510	-8,573 Reduced 4.46%	183,740 $2.83 Million
Q3 2020 Nov 16, 2020	SELL	$10.82 - $13.35 $187,240 - $231,021	-17,305 Reduced 8.26%	192,313 $2.13 Million
Q2 2020 Aug 14, 2020	BUY	$10.21 - $14.9 $685,193 - $999,939	67,110 Added 47.09%	209,618 $2.63 Million
Q1 2020 May 15, 2020	BUY	$8.08 - $17.57 $772,698 - $1.68 Million	95,631 Added 204.0%	142,508 $1.62 Million
Q4 2019 Feb 14, 2020	BUY	$8.11 - $14.65 $129,589 - $234,092	15,979 Added 51.72%	46,877 $615,000
Q3 2019 Nov 14, 2019	BUY	$8.74 - $10.51 $1,153 - $1,387	132 Added 0.43%	30,898 $278,000
Q2 2019 Aug 14, 2019	SELL	$8.51 - $10.75 $211,609 - $267,309	-24,866 Reduced 44.7%	30,766 $303,000
Q1 2019 May 15, 2019	SELL	$6.39 - $10.42 $483,007 - $787,626	-75,588 Reduced 57.6%	55,632 $565,000
Q4 2018 Feb 14, 2019	BUY	$5.61 - $12.62 $736,144 - $1.66 Million	131,220 New	131,220 $828,000

Others Institutions Holding XENE

# of Institutions

220

Shares Held

69.6M

Call Options Held

59.7K

Put Options Held

60.7K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.54B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account